Effectiveness of Oral Nirmatrelvir/Ritonavir vs. Intravenous Three-Day Remdesivir in Preventing Progression to Severe COVID-19: A Single-Center, Prospective, Comparative, Real-Life Study

Effectiveness of Oral Nirmatrelvir/Ritonavir vs. Intravenous Three-Day Remdesivir in Preventing Progression to Severe COVID-19: A Single-Center, Prospective, Comparative, Real-Life Study

Background: Nirmatrelvir/ritonavir (NMV/r) and three-day course remdesivir (3RDV) have been approved as early treatments for COVID-19 outpatients not requiring supplemental oxygen. Real-life data on the efficacy of antivirals among immunocompromised patients or directly comparing their effectiveness...

Full description

Bibliographic Details
Main Authors: Dimitrios Basoulis, Aristeidis Tsakanikas, Aikaterini Gkoufa, Aikaterini Bitsani, Georgios Karamanakos, Elpida Mastrogianni, Vasiliki E. Georgakopoulou, Sotiria Makrodimitri, Pantazis-Michail Voutsinas, Panagiota Lamprou, Athanasios Kontos, Stathis Tsiakas, Maria N. Gamaletsou, Smaragdi Marinaki, Nikolaos V. Sipsas
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Viruses
Subjects:
nirmatrelvir/ritonavir
remdesivir
COVID-19
inverse-probability of treatment weighting
immunocompromised patients
Online Access:https://www.mdpi.com/1999-4915/15/7/1515

Internet

https://www.mdpi.com/1999-4915/15/7/1515

Similar Items